Trial Profile
A Phase I, Randomized, Placebo-controlled, Open-label, Three Period Crossover Study to Investigate the Effect of Darolutamide and Enzalutamide on Cerebral Blood Flow in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Darolutamide (Primary) ; Enzalutamide (Primary)
- Indications Bladder cancer; Breast cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer
- Focus Pharmacodynamics
- Sponsors Bayer
- 27 Apr 2023 Primary endpoint (Change in grey-matter cerebral blood flow of darolutamide as compared to placebo) has not been met, according to a results published in the Targeted Oncology.
- 27 Apr 2023 Primary endpoint (Change in grey-matter cerebral blood flow of enzalutamide as compared to darolutamide) has been met, according to a results published in the Targeted Oncology.
- 27 Apr 2023 Primary endpoint (Change in grey-matter cerebral blood flow of enzalutamide as compared to placebo) has been met, according to a results published in the Targeted Oncology.